Combined effect of HLA-DRB1* 1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis

Journal of Neuroimmunology

Volumn 80, Issue 1-2, 1997, Pages 172-178

  De La Concha, E G ^a   Arroyo, R ^a   Crusius, J B A ^a   Campillo, J A ^a   Martin, C ^a   Varela De Seijas, E ^a   Pena A S ^b   Claveria L E ^c   Fernandez Arquero, M ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

Disease susceptibility; HLA class II genotyping; Interleukin 1 receptor antagonist gene; Multiple selerosis

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ALLELES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FEMALE; GENE FREQUENCY; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MULTIPLE SCLEROSIS; RANDOM ALLOCATION; RECEPTORS, INTERLEUKIN-1; RECURRENCE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SIALOGLYCOPROTEINS; SPAIN;

EID: 0031454972     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00153-7     Document Type: Article

References (37)

1. Allen M., Sandberg-Wollheim M., Sjögren K., Erlich H.A., Petterson U., Gyllensten U. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum. Immunol. 39:1994;41-48.
2. Beall S.S., Concannon P., Charmley P., McFarland H.F., Gatti R.A., Hood L.E., McFarlin D.E., Biddison W.E. The germline repertoire of T cell receptor beta chain genes in patients with chronic progressive multiple sclerosis. J. Neuroimmunol. 21:1989;59-66.
3. Bell J.I., Lathrop G.M. Multiple loci for multiple sclerosis. Nature Genet. 13:1996;377-378.
4. Canella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37:1995;424-435.
5. Compston D.A.S., Kellar Wood H., Robertson N., Sawcer S., Wood N.W. Genes and susceptibility to multiple sclerosis. Acta Neurol. Scand. Suppl. 161:1995;43-51.
6. Crusius J.B.A., Peña A.S., van Oosten B.W., Bioque G., Garcia A., Dijkstra C.D., Polman C.H. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet. 346:1995;979-980.
7. Ebers G.C., Kukay K., Bulman D.E., Sadovnick A.D., Rice G., Anderson C., Armstrong H., Cousin K., Bell R.B., Hader W., Paty D.W., Hashimoto S., Oger J., Duquette P., Warren S., Gray T., O'Connor P., Nath A., Auty A., Metz L., Francis G., Paulseth J.E., Murray T.J., Pryse-Phillips W., Nelson R., Freedman M., Brunet D., Bouchard J.-P., Hinds D., Risch N. A full genome search in multiple sclerosis. Nature Genet. 13:1996;472-476.
8. Epplen C., Jäckel S., Santos E.J.M., D'Souza M., Poehlau D., Dotzauer B., Sindern E., Haupts M., Rüde K.-P., Weber F., Stöver J., Poser S., Gehler W., Malin J.-P., Przuntek H., Epplen J.T. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann. Neurol. 41:1997;341-352.
9. Haegert D.G., Muntoni F., Murru M.R., Costa G., Francis G.S., Marrosu M.G. HLA-DQA1 and -DQB1 associations with multiple sclerosis in Sardinia and French Canada: evidence for immunogenetically distinct patient groups. Neurology. 43:1993;548-552.
10. Haegert D.G., Swift F.V., Benedikz J. Evidence for a complex role of HLA class II genotypes in susceptibility to multiple sclerosis in Iceland. Neurology. 46:1996;1107-1111.
11. Haines J.L., Ter-Minassian M., Bazyk A., Gusella J.F., Kim D.J., Terwedow H., Pericak-Vance M.A., Rimmler J.B., Haynes C.S., Roses A.D., Lee A., Shaner B., Menold M., Seboun E., Fitoussi R.-P., Gartioux C., Reyes C., Ribierre F., Gyapay G., Weissenbach J., Hauser S.L., Goodkin D.E., Lincoln R., Usuku K., Garcia-Merino A., Gatto N., Young S., Oksenberg J.R. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nature Genet. 13:1996;469-471.
12. Hauser S.L. Tumor necrosis factor: immunogenetics and disease. Ann. Neurol. 38:1995;702-704.
13. Hillert J., Grönning M. Jr., Nyland H., Link H., Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 55:1992;887-890.
14. Huang W.-X., He B., Hillert J. An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J. Neuroimmunol. 67:1996;143-144.
15. Kimura, A., Sasazuki, T., 1991. Eleventh International Histocompatibility workshop reference protocol for the HLA DNA-typing technique. In: Tsuji, K., Aizawa, M., Sasazuki, T. (Eds.), HLA 1991, Vol. 1. Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Oxford University Press, Oxford, pp. 397-419.
16. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
17. Marrosu M.G., Muntoni F., Murru M.R., Spinicci G., Pischedda M.P., Goddi F., Cossu P., Pirastu M. Sardinian multiple sclerosis is associated with HLA-DR4: a serologic and molecular analysis. Neurology. 38:1988;1749-1753.
18. Martin D., Near S.L. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J. Neuroimmunol. 61:1995;241-245.
19. Martinez-Naves E., Victoria-Gutierrez M., Uría D.F., Lopez-Larrea C. The germline repertoire of T cell receptor beta-chain genes in multiple sclerosis patients from Spain. J. Neuroimmunol. 47:1993;9-14.
20. Newton-Nash D.K., Eckels D.D. Differential effect of polymorphism at HLA-DR1 β-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides. J. Immunol. 150:1993;1813-1821.
21. Oksenberg J.R. Immunogenetics and heterogeneity in multiple sclerosis. Ann. Neurol. 40:1996;557-558.
22. Olerup O., Hillert J., Fredrikson S., Olsson T., Kam-Hansen S., Moller E., Carlsson B., Wallin J. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct entities. Proc. Natl. Acad. Sci. USA. 86:1989;7113-7117.
23. 86 HLA-DRβ dimorphism in autoantigen presentation to human T cells. Proc. Natl. Acad. Sci. USA. 88:1991;7343-7347.
24. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
25. Robertson N.P., Clayton D., Fraser M., Deans J., Compston D.A.S. Clinical concordance in sibling pairs with multiple sclerosis. Neurology. 47:1996;347-352.
26. Sadovnick A.D., Ebers G.C. Genetics of multiple sclerosis. Neurol. Clin. 13:1995;99-118.
27. Canadian Collaborative Study Group, Sadovnick A.D., Ebers G.C., Dyment D.A., Risch N.J. Evidence for genetic basis of multiple sclerosis. Lancet. 347:1996;1728-1730.
28. Sawcer S., Jones H.B., Feakes R., Gray J., Smaldon N., Chataway J., Robertson N., Clayton D., Goodfellow P.N., Compston A. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Med. 13:1996;464-468.
29. Sawcer S., Goodfellow P.N., Compston A. The genetic analysis of multiple sclerosis. Trens Genet. 13:1997;234-239.
30. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
31. Tarlow J.K., Blakemore A.I.F., Lennard A., Solari R., Hughes H.N., Steinkasserer A., Duff G.W. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86 bp tandem repeat. Hum. Genet. 91:1993;403-404.
32. Tienari P.J. Multiple sclerosis: multiple etiologies, multiple genes? Ann. Med. 26:1994;259-269.
33. Tienari P.J., Wikstrom J., Sajantila A., Palo J., Peltonen L. Genetic susceptibility to multiple sclerosis linked to myelin basic protein gene. Lancet. 340:1993;987-991.
34. Van Lambalgen R., Sanders E.A.C.M., D'Amaro J. Sex distribution, age of onset and HLA profiles in two types of multiple sclerosis. A role for sex hormones and microbial infections in the development of autoimmunity? J. Neurol. Sci. 76:1986;13-21.
35. Walter M.A., Gibson W.T., Ebers G.C., Cox D.W. Susceptibility to multiple sclerosis is associated with the proximal immunoglobulin heavy chain variable region. J. Clin. Invest. 87:1991;1266-1273.
36. Weiner H.L., Mackin G.A.S., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., Hafler D.A. Double blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 259:1993;1321-1324.
37. Wood N.W., Sawcer S.J., Kellar-Wood H.F., Holmans P., Clayton D., Robertson N., Compston D.A.S. The T-cell receptor beta-locus and susceptibility to multiple sclerosis. Neurology. 45:1995;1859-1863.